Lupin Limited (NSE:LUPIN)

Market Cap	1.04T +9.4%
Revenue (ttm)	279.58B +23.1%
Net Income	53.33B +62.5%
EPS	116.44 +62.4%
Shares Out	n/a
PE Ratio	19.54
Forward PE	22.66
Dividend	12.00 (0.53%)
Ex-Dividend Date	Jul 25, 2025

Volume	1,225,126
Average Volume	1,540,286
Open	2,297.00
Previous Close	2,284.50
Day's Range	2,270.00 - 2,304.50
52-Week Range	1,836.80 - 2,494.00
Beta	0.23
RSI	47.33
Earnings Date	May 7, 2026

About Lupin

Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India, the United States, and internationally. The company operates in two segments: Pharmaceuticals and Others. It engages in the drug discovery, development, production, marketing, and sale of various branded and generic formulations, biosimilars, over-the-counter and specialty drugs, and active pharmaceutical ingredients (APIs). The company also offers formulations for use in the therapeutic areas of anti-tuberculosis, diabetes management, cardiovascular, ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1968
• Employees: 24,006
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: LUPIN

Financial Performance

In fiscal year 2026, Lupin's revenue was 279.58 billion, an increase of 23.12% compared to the previous year's 227.08 billion. Earnings were 53.33 billion, an increase of 62.51%.